PDCD2L

Across TCGA pan-cancer cohorts, PDCD2L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PDCD2L data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PDCD2L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD2L expression acts as an unfavorable survival marker.

OV, PAAD, and SCLC are the cancer types where PDCD2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
BRCA	OS	Median	All	0.410	0.924	<.001	12	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
LIHC	DFS	Median	All	0.116	0.555	.010	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PDCD2L–OV (OS)

Open the OV breakdown →